Publicacions en col·laboració amb investigadors/es de Centro de Investigación Médica Aplicada (38)

2024

  1. GeNNius: an ultrafast drug-target interaction inference method based on graph neural networks

    Bioinformatics (Oxford, England), Vol. 40, Núm. 1

  2. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer (Molecular Cancer, (2023), 22, 1, (86), 10.1186/s12943-023-01788-w)

    Molecular Cancer

  2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  3. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition

    European Journal of Cancer, Vol. 174, pp. S47

  2. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

2020

  1. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy

    EBioMedicine, Vol. 53

  2. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  3. Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations

    Journal of Thoracic Oncology

  4. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

  5. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

    Nature Medicine, Vol. 25, Núm. 11, pp. 1783-1795

  2. Genetic mouse models as in vivo tools for cholangiocarcinoma research

    Cancers, Vol. 11, Núm. 12

  3. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  4. P65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  5. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery

    Cancer Letters, Vol. 453, pp. 21-33

2018

  1. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

  2. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects

    American Journal of Respiratory and Critical Care Medicine, Vol. 197, Núm. 9, pp. 1164-1176

  3. Cancertool: A visualization and representation interface to exploit cancer datasets

    Cancer Research, Vol. 78, Núm. 21, pp. 6320-6328